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ABSTRACT: Targeted approaches aiming at modulating NHERF1 activity, rather than its overall expression, would be
preferred to preserve the normal functions of this versatile protein. We focused our attention on the NHERF1/PDZ1 domain
that governs its membrane recruitment/displacement through a transient phosphorylation switch. We herein report the design
and synthesis of novel NHERF1 PDZ1 domain inhibitors. These compounds have potential therapeutic value when used in
combination with antagonists of β-catenin to augment apoptotic death of colorectal cancer cells refractory to currently available
Wnt/β-catenin-targeted agents.
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NHERF1 (Na+/H+ exchanger 3 regulating factor 1) is an
integral membrane adaptor protein of 358 amino acids carrying
two NH2-terminal PDZ (postsynaptic density 95/discs large/
zona occludens 1) tandem domains.1 PDZ1 (11−97 amino
acids) and PDZ2 (150−237 amino acids) show 74% identity
to each other and bind to specific carboxyl-terminal motifs on
target proteins, such as β-catenin and PTEN, that may have a
pivotal role in tumorigenesis. Oncogenic activity of NHERF1
is strictly dictated by changes on its subcellular localization.1,2
While a loss of its physiologic membranous expression usually
occurs in early dysplastic human adenomas, especially those of
colon and breast, NHERF1 is progressively re-expressed
throughout the cytoplasm and nuclei in highly invasive/
metastatic carcinomas. Recent evidence also earmarked
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NHERF1 as a major driver of a cytoprotective autophagic
response elicited by therapeutic inhibition of the Wnt/β-
Catenin signaling cascade, which triggers colorectal cancers
(CRC).3 Notably, these studies have started to explore a
combined β-catenin/NHERF1-inhibitory strategy as a fruitful
approach to augment apoptotic death of CRC cells refractory
to currently available Wnt-targeted agents, particularly at early
stages of the disease.
Previous studies focused on small-molecule ligands of the
PDZ1-domain of NHERF1 to prevent its ectopic cytoplasmic/
nuclear mislocalization and oncogenic function.4−6 These
studies predicted the canonical inactivating binding motif for
the NHERF1 PDZ1-domain on four D/E-(S/T)-X-(L/V/I/
M) residues that are commonly contained at the C-terminal of
its specific ligands, such as DSLL for the β2-adrenergic
receptor (β2-AR) or ETWM for the parathyroid hormone
receptor (PTHR).7
The crystal structure of the PDZ1-β2-AR C-terminal peptide
is available at the protein data bank (PDB code 1GQ4).8 The
complex was fixed by cutting the chimeric covalent bond
between PDZ1 and the substrate (-NDSLL) and submitted to
molecular dynamics (MD) simulations to obtain reasonable
binding conformations. MD of the complex PDZ1-PTH1R C-
terminal peptide (WETVM) was also performed (Figures 1S
and 2S, Supporting Information). Trajectory analyses showed
that the systems were stable during a simulation time of 50 ns,
with an average PDZ1 Cα RMSD of 1.66 and 1.73 Å for
PDZ1-NDSLL-COOH and PDZ1-WETVM-COOH, respec-
tively. The main interactions between the PDZ1 and the -β2-
AR substrate observed at the crystal structures were retained
during the MD simulations (Supporting Information). The
trajectories were clustered by the RMSDs of the binding site
residues, giving five clusters for the two studied complexes,
each containing representative structures. The obtained 10
structures guided the design of a pharmacophore model
(Figure 3S, Supporting Information) that was used to filter out
an in-house training set of about 6000 compounds. One out of
six selected compounds showed significant NHERF1 inhib-
ition.3 We herein report the design and synthesis of new
NHERF1 inhibitors 1−14. In preliminary docking studies,
these compounds matched the requirements of the pharma-
cophore model, in particular, the interactions at the t-COOH
binding pocket.9
Compounds 1−14 were synthesized starting from 5-chloro-
1H-indole-2-carboxylic acid (18) or its 3-isomer 19 (Scheme
1, Supporting Information). The acids were transformed into
the corresponding acyl chlorides with thionyl chloride and
coupled with an appropriate aminobenzoate in dichloro-
methane in the presence of pyridine to afford carboxamides
20−24. Hydrolysis of the ester functionality of 20−24 was
performed with lithium hydroxide monohydrate in tetrahy-
drofuran (5 and 6) or with 3 N sodium hydroxide in ethanol at
25 °C (7, 11, and 12). Alcohol derivatives 1, 3, 4, and 8−10
were obtained by tetrabutylammonium fluoride cleavage in
tetrahydrofuran at 25 °C of the corresponding tert-
butyldimethylsilyl derivatives 25−30. The latter compounds
were prepared by reaction of 18 or 19 with tert-
butyldimethylsilyloxymethylanilines 31−33. Carboxamides 2,
13, 25−30, and 34 were synthesized from the corresponding
anilines in the presence of tripyrrolidinophosphonium
hexafluorophosphate (PyBOP) and triethylamine in DMF at
25 °C. Compound 14 was obtained after lithium hydroxide of
the intermediate methyl tyrosinate 34.
The ability of 1−14 to inhibit NHERF1 was assessed in
Ls174T CRC cells harboring a doxycycline hyclate (Dox)-
inducible small hairpin RNA (shRNA) for β-catenin
(Ls174Tshβ-Cat) (Table 1). Our published data indicated
that such CRC cells exhibited low/undetectable NHERF1
levels at the baseline (i.e., in the absence of Dox), while they
markedly increase the expression of the protein as well as a
NHERF1-mediated survival response under Dox treatment.3
The relative activity of 1−14 can be explained by Δ values
obtained by subtracting the IC50 values of the Ls174Tshβ-Cat
cells cultured in the presence or in the absence of Dox. Indeed,
NHERF1/PDZ-1 ligand inhibitors are expected to exert their
growth-inhibitory effects only on β-catenin-depleted CRC
cells, which highly re-expressed the protein target NHERF1,
thus showing the highest Δ values with regard to Dox-
untreated cells. Introduction of a methylene spacer between
the 2-carboxamide function and the phenyl group of 1 (−Dox
IC50 = 62 μM; +Dox IC50 = 24 μM) to afford 4 gave a slight
improvement of activity. Moving the hydroxymethyl group of 1
from para to meta (3) or ortho (4) only minimally affected the
Table 1. Structure and Activity of Compounds 1−14 in
Ls174TshβCat Cells Expressing Low (−DOX) or High
(+DOX) Levels of the Protein Target NHERF1a
aLs174T cells stably transfected with Dox-inducible shRNA for β-
catenin (Ls174Tshβ-Cat) were cultured without or with 2 μg/mL of
Dox (−Dox/+Dox) for 1, 3, or 5 days.
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difference (Δ) of activity between the two cell lines.
Replacement of the hydroxymethyl of 1 with a carboxylic
acid function (5) (−Dox IC50 = 74 μM; +Dox IC50 = 12 μM)
improved the Δ value from 38 to 62, while the corresponding
meta (6) or ortho (7) carboxylic acids gave similar results for
2−4. We synthesized the corresponding analogues 8−14 at
position 3 of the indole. Derivatives 9 (−Dox IC50 = 82 μM;
+Dox IC50 = 8 μM) and 10 (−Dox IC50 = 84 μM; +Dox IC50
= 5 μM) bearing the hydroxymethyl at positions meta and
ortho (Δ of 74 and 79, respectively) were superior to the para
analogue 7 as well as to the carboxylic acids 11 and 12. The 3-
indolecarboxamide 13 (−Dox IC50 = 85 μM; +Dox IC50 = 10
μM) yielded a good Δ value of 75 that was 1.8-fold superior to
the isomeric derivative 1. In sum, compounds 5, 9, 10, and 13
exhibited a remarkable cytotoxicity and the highest Δ values on
Ls174Tshβ-Cat, which highly re-express the specific protein
target NHERF1.
The indole NH and the carboxamide oxygen formed H-
bonds with the Leu27 backbone. Hydrophobic contacts were
observed between the phenyl ring and Tyr24, Phe26, and Ile78
as well as between the indole ring and Val75 and Val76. It is
noteworthy that the carboxylic group of derivatives 5−7
formed polar contacts with the Arg80 (Figure 1, top panel).
Derivatives 8−14 showed binding modes with different
patterns in H-bonding. In comparing the alcohol 9 and its
corresponding carboxylic acid 12, the indole NH formed an H-
bond with the His72 backbone, the amide oxygen atom formed
an H-bond with the His27 side chain, the indole ring
established hydrophobic contacts with Leu28 and Val75, the
phenyl ring arranged hydrophobic contacts with Tyr24 and
Phe26, and a π-cation interaction with the guanidine moiety of
Arg80 occurred. The alcohol and the carboxyl moieties were
involved in H-bond/polar contact with the terminal COOH
binding pocket (Figure 1, bottom panel).
The binding of 9, 10, and 13 to NHERF1 PDZ1 was
assessed by means of a dansylated peptide corresponding to
the C-terminal sequence of β2-AR (DNDSLL) using a a
fluorescent pseudowild type produced by replacing Tyr38 of
PDZ1 with a Trp.9 The presence of a constant concentration
of 9, 10, or 13 abolished the binding C-terminal sequence of
β2-AR with an affinity of about 10 μM, thus validating these
compounds as specific inhibitors of the NHERF1/PDZ1
domain (Figure 2). To further test the ability of 9, 10, and 13
to bind NHERF1 PDZ1, we performed urea-induced
denaturation in the presence of the inhibitors. In fact, the
ability to bind the native, rather than the denatured, state of
the protein induces a stabilization of the domain. Such a
stabilization is correlated to the affinity of the compounds to
PDZ1 NHERF1 (Figure 4S, Supporting Information). The
results provide compelling evidence of the inhibition of
NHERF1 PDZ1 by derivatives 9, 10, and 13.
Derivatives 5, 9, 10, and 13 with the highest Δ values as
inhibitors of Ls174Tshβ-Cat cells were also tested in three
CRC cell lines, such as DLD-1, SW480, and SW620. It is
known that NHERF1 is expressed at detectable baseline levels
in SW480 and SW620 but not in DLD-1 cells.3 This relatively
explains why DLD-1 cells showed the highest IC50 values
compared to SW480 and SW620 cells (Table 2) at micromolar
concentrations quite similar to those previously obtained in
Dox-untreated Ls174Tshβ-Cat cells (Table 1) (additional
cancer cell lines are reported in Table 1S, Supporting
Information).
We previously reported that 3-benzyl-5-chloro-N-(4-
(hydroxymethyl)phenyl)-1H-indole-2-carboxamide (15), a
NHERF1 PDZ1 inhibitor with −Dox IC50 = 52 μM and
+Dox IC50 = 8 μM synergized N-(2-methyl-4-nitrophenyl)-2,5-
dichlorobenzenesulfonamide (FH535, 16) and the pyrvinium
pamoate inhibitor of β-catenin-dependent transcription in
triggering massive apoptosis of Ls174T and DLD1 CRC cells,
thereby preventing persistent ERK1/2 phospho-activation
mediated by single β-Catenin targeting.3,10,11 We therefore
speculated the potential benefit of a synergic activity of
NHERF1 PDZ1 and β-catenin inhibitors in CRC therapy.
We compared 10, the compound with the highest Δ value
within this series, and 15,3 with two β-Catenin inhibitors,
FH535 (16)12 and 17 (Chart 1S, Supporting Information). We
Figure 1. Proposed binding modes. Top panel: derivatives 5 (cyan), 6
(orange), and 7 (magenta). Bottom panel: derivatives 9 (cyan) and
12 (orange). Residues involved in interactions are reported as stick.
PDZ1 is reported as cartoon (green). The H-bonds are depicted as
yellow dotted lines.
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tested the effect of increasing concentrations of 17 on the Wnt
signaling pathway by performing Wnt reporter assays in 293T
cells. We transfected TOPFlash (TOP) reporter plasmid,
containing eight repeats of TCF/LEF binding site or
FOPFlash (FOP) plasmid, where the TFC/LEF binding sites
were mutated as negative control.13 The Wnt pathway was
activated using the GSK3beta inhibitor LiCl. Compound 17
inhibited the activity of the TOP reporter, with an IC50 of 14.1
μM (Figure 5S, Supporting Information). Conversely, this
compound failed to prevent the activity of FOP reporter,
indicating the specificity of the inhibition of the Wnt pathway.
Indeed, a 1:1 combination of a NHERF1 inhibitor with a β-
catenin inhibitor significantly improved the growth inhibition
of all CRC cells. All combinations were superior to each single
tested compound in DLD-1 and SW480 cells. Compound
combinations 10 + 17, 15 + 16, and 15 + 17 inhibited the
SW480 cells at submicromolar concentrations, and the most
potent combination was 15 + 17 (IC50 = 0.1 μM).
Combinations 10 + 17 and 15 + 17 showed the higher
effectiveness, and 15 + 17 was the most potent with IC50
values of 0.1 and 0.5 μM (Table 3).
Cancer stem cells (CSCs) have received growing interest
during the last years because they have proved to be selectively
resistant to chemotherapics, thus giving an explanation to the
relapse that in most cases follows fast tumor shrinkage induced
by standard therapies. In this frame, the identification of
targeted drugs active on CSCs may give hope of full tumor
eradication. Preliminary screening of two APC-mutated CSCs
indicated that their sensitivity to compounds 10 and 17 was
broadly comparable to that of standard cell lines (Table 4).
Analysis on a wider panel of CSCs is ongoing in order to verify
a possible role of different mutational profiles of individual
CSCs on drug sensitivity.
Since physiological or pathological roles of NHERF1 are
related to its subcellular localization, targeted approaches
aiming at modulating NHERF1 activity, rather than its overall
expression, would be preferred to preserve the normal
functions of this versatile protein. By far, particular attention
has been paid to the NHERF1/PDZ1-domain that governs its
membrane recruitment/displacement through a transient
phosphorylation switch. We herein characterized novel
NHERF1 PDZ1 domain inhibitors with therapeutic value
when used in combination with antagonists of β-catenin. This
double-targeted strategy shows potential to augment apoptotic
death of CRC cells refractory to currently available Wnt-
targeted agents, particularly at early stages of the disease.
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Figure 2. Binding of PDZ1 NHERF1 Y38W to the ligand dansyl-
NDSLL in the presence (black circles) and in the absence of 5 μM of
9 (green), 10 (red), or 13 (blue). Fluorescence data were recorded in
the presence of 50 mM Na phosphate pH 7.2, 300 mM NaCl, 5 mM
DTT, 20% DMSO, at 25 °C. Lines are the best fit to a hyperbolic
binding transition. The binding between PDZ1 NHERF1 Y38W to
the ligand dansyl-NDSLL was abolished in the presence of 9, 10, or
13.
Table 2. Cell Growth Inhibition of DLD-1, SW480, and
SW620 Cell Lines by Compounds 5, 9, 10, and 13a
IC50 (μM)
compd DLD-1 SW480 SW620
5 68 ± 1 17 ± 1 22 ± 1
9 82 ± 2 13 ± 1 27 ± 1
10 85 ± 2 15 ± 1 30 ± 1
13 84 ± 2 16 ± 1 31 ± 1
aCytotoxic concentrations for the indicated cell lines. Experiments
were performed in triplicate and repeated at least twice.
Table 3. Synergistic Cell Growth Inhibition of SW480 and
SW620 Cell Lines by Compounds 10, 15, 16, and 17a,b
IC50 (μM)
compd inhibitor DLD-1 SW480 SW620
10 NHERF1 85 ± 2 15 ± 1 30 ± 1
15 NHERF1 65 ± 11 8 ± 1 13 ± 2
16 β-Cat 28 ± 5 10 ± 2 19 ± 1
17 β-Cat 21 ± 2 8 ± 2 17 ± 1
10 + 16 NHERF1 + β-Cat 0.8 ± 2 3.0 ± 2 22 ± 2
10 + 17 NHERF1 + β-Cat 0.1 ± 2 0.3 ± 2 12 ± 2
15 + 16 NHERF1 + β-Cat 0.5 ± 3 0.9 ± 2 18 ± 1
15 + 17 NHERF1 + β-Cat 0.1 ± 2 0.1 ± 2 0.5 ± 2
aCytotoxic concentrations for the indicated cell lines. Experiments
were performed in triplicate repeated at least twice. bCompound
combinations were in a 1:1 ratio.
Table 4. Cell Growth Inhibition of CSC13 and CSC8
Cancer Stem Cell Lines by Compounds 10 and 17a
IC50 (μM)
compd inhibitor CSC13 CSC8
10 NHERF1 12 ± 1 8 ± 1
17 β-Cat 22 ± 2 13 ± 2
aCytotoxic concentrations for the indicated CSCs. Experiments were
performed in triplicate repeated at least twice.
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